Literature DB >> 1153691

The treatment of acromegaly with special reference to trans-sphenoidal hypophysectomy.

R A Williams, H S Jacobs, A B Kurtz, J G Millar, N W Oakley, G S Spathis, M J Sulway, J D Nabano.   

Abstract

Experience in the management of 100 cases of acromegaly is described. Three quarters of these had been referred directly to the endocrine clinic at the Middlesex Hospital. The remainder were referred from the Royal Post-graduate Hospital because they were thought unsuitable for yttrium implantation. The patients were studied by clinical assessment of severity, by measurement of basal growth hormone levels on three separate mornings, and by a review of possible complications. Particular attention was paid to diabetes, hypertension, cardiomegaly, respiratory, vascular and skeletal changes as well as visual field defect. Aggressive treatment was recommended in 77 patients. It was not recommended in the remainder on account of age, intercurrent illness or the apparent mildness of the condition. Fifty-nine patients were treated by trans-sphenoidal hypophysectomy. In 46 of the 59 patients the mean basal growth hormone level has been reduced to 5 ng/ml or less. In 39 this followed operation, in five operation and subsequent X-ray therapy and in two operation and the continuing effect of previously implanted yttrium. Of these 46 patients in whom the growth hormone level has been reduced to normal, 26 do not show any deficiency of anterior pituitary trophic hormones, 13 have gonadotrophin defect (in eight of these it was present before the operation) and seven require full replacement therapy. One patient died at home six weeks after the operation from a pulmonary embolus. There was one case of CSF rhinorrhoea which stopped spontaneously and three of acute frontal sinusitis. Trans-sphenoidal hypophysectomy is shown to be an effective means of treating acromegaly. If the basal level of growth hormone is not reduced to normal by six weeks after operation, it is recommended that a course of X-ray therapy should be given. This does not apply if irradiation has been used before operation.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1153691

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  11 in total

1.  Management of acromegaly.

Authors:  J D Nabarro
Journal:  J Clin Pathol Suppl (Assoc Clin Pathol)       Date:  1976

2.  Transsphenoidal surgery for pituitary tumours.

Authors:  A F Massoud; M Powell; R A Williams; P C Hindmarsh; C G Brook
Journal:  Arch Dis Child       Date:  1997-05       Impact factor: 3.791

Review 3.  Bromocriptine in the treatment of acromegaly.

Authors:  D E Bateman; W M Tunbridge
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

4.  Acromegaly with 'normal' growth hormone levels.

Authors:  K R Feingold; T J Lorenz
Journal:  West J Med       Date:  1985-01

Review 5.  Treatment of acromegaly.

Authors:  J P Thomas
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-29

6.  Conservative removal of small pituitary tumours: is it justified by the pathological findings?

Authors:  P Wrightson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-03       Impact factor: 10.154

7.  Reduction in sella turcica volume. An effect of long-term treatment with the somatostatin analogue, SMS 201-995, in acromegalic patients.

Authors:  E Lund; J Jørgensen; S E Christensen; J Weeke; H Orskov; A G Harris
Journal:  Neuroradiology       Date:  1991       Impact factor: 2.804

Review 8.  Epidemiology of acromegaly.

Authors:  I M Holdaway; C Rajasoorya
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

9.  Bromocriptine therapy in acromegaly. A long-term review of 35 cases.

Authors:  Y Sachdev; K Gopal; V K Garg
Journal:  Postgrad Med J       Date:  1981-04       Impact factor: 2.401

Review 10.  Recent developments in acromegaly: a review.

Authors:  A Jadresic
Journal:  J R Soc Med       Date:  1983-11       Impact factor: 18.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.